Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in Thailand

Coronavirus disease 2019 affected child health and impacted learning because of the resulting onsite school closures. This prospective cohort study included children aged 10–17 who received two 4 µg doses of BBIBP-CorV administered intramuscularly 21–28 days apart. To assess vaccine safety, 36,808 p...

Full description

Bibliographic Details
Main Authors: Saraiorn Thonginnetra, Kriangkrai Tawinprai, Krongkwan Niemsorn, Pathariya Promsena, Manunya Tandhansakul, Naruporn Kasemlawan, Natthanan Ruangkijpaisal, Narin Banomyong, Nanthida Phattraprayoon, Pisuttikan Rangkakulnuwat, Preeda Vanichsetakul, Teerapat Ungtrakul, Kasiruck Wittayasak, Nawarat Thonwirak, Kamonwan Soonklang, Nithi Mahanonda
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Vaccines
Subjects:
Online Access:https://www.mdpi.com/2076-393X/10/10/1765